Login / Signup

HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens.

Enora LaasArnaud BressetJean-Guillaume FéronClaire Le GalLauren DarriguesFlorence CoussyBeatriz GrandalLucie LaotJean-Yves PiergaFabien ReyalAnne Sophie Hamy
Published in: Cancers (2021)
In patients with HER2-positive BC, the NAC strategy is more beneficial than the AC strategy, particularly in cN-positive and postmenopausal patients. NAC should be used as a first-line treatment for HER2-positive tumors.
Keyphrases